Aclaris Therapeutics ACRS Deferred Transaction Consideration In Connection With In License Agreement
Deferred Transaction Consideration In Connection With In License Agreement at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:DeferredTransactionConsiderationInConnectionWithInLicenseAgreement.
The official record: Aclaris Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's deferred transaction consideration in connection with in license agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's deferred transaction consideration in connection with in license agreement?
- Aclaris Therapeutics (ACRS) reported deferred transaction consideration in connection with in license agreement of $1.56M in Q4 2024.
- What does deferred transaction consideration in connection with in license agreement mean?
- This captures the value of future payment obligations incurred as part of an in-licensing agreement for new drug candidates or technologies. It represents a contractual commitment to pay for intellectual property rights over time. Monitoring this is vital for assessing long-term financial obligations and the total cost of external innovation partnerships.